natgillin/translations-raw huggingface dataset:
Two dose-dependent responses are seen: At high concentrations (10 mcg/mL or more), cells entering mitosis are lysed; at low concentrations (0.3 to 10 mcg/mL), cells are inhibited from entering prophase.
Kaže Kaže dvojno od odmerka odvisno delovanje: pri višjih koncentracijah (10 μg/ml ali več) pride do lize celic, ki vstopajo v mitozo.
• difficulty breathing
• neplodnost • težave z dihanjem
In all instances where the use of ETOPOPHOS and associated names is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risk of adverse reactions.
Zdravnik mora pred uporabo zdravila ETOPOPHOS in povezana imena ovrednotiti potrebo in koristnost zdravljenja glede na tveganje za neželene učinke.
Etoposide phosphate
Odmerek etopozid fosfata
If ETOPOPHOS and associated names solution contacts the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water.
Če pride zdravilo ETOPOPHOS in povezana imena v stik s kožo ali sluznico, je treba kožo takoj umiti z milom in vodo, sluznico pa izprati z vodo.
The recommended dose of ETOPOPHOS and associated names is 50 to 100 mg/m2/day (etoposide equivalent) on days 1 to 5 or 100 to 120 mg/m2 on days 1, 3, and 5 every 3 to 4 weeks in combination with other drugs indicated in the disease to be treated.
Priporočeni odmerek zdravila ETOPOPHOS in povezana imena je 50 do 100 mg/m2/dan (ekvivalent etopozida) na 1. do 5. dan ali 100 do 120 mg/m2 na 1., 3. in 5. dan na vsake 3 do 4 tedne v kombinaciji z drugimi zdravili, indiciranimi za zdravljenje bolezni.
Concomitant phenytoin therapy is associated with increased etoposide clearance and reduced efficacy, and other enzyme-inducing antiepileptic therapy may be associated with increased ETOPOPHOS and associated names clearance and reduced efficacy.
Tudi druga protiepileptična zdravila, ki inducirajo encime, so lahko povezana s povečanim očistkom zdravila ETOPOPHOS in povezana imena in z njegovo zmanjšano učinkovitostjo.
ETOPOPHOS and associated names in paediatric patients has been used in the range of 75 to 150 mg/m2/day (etoposide equivalent) for 2 to 5 days in combination with other antineoplastic agents.
Zdravilo ETOPOPHOS in povezana imena so pri pediatričnih bolnikih uporabljali v razponu od 75 do 150 mg/m2/dan (ekvivalent etopozida) 2 do 5 dni v kombinaciji z drugimi zdravili z delovanjem na novotvorbe.
How you will be given ETOPOPHOS and associated names
Kako boste prejeli zdravilo ETOPOPHOS in povezana imena
If etoposide phosphate should contact the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water.
Če pride etopozid fosfat v stik s kožo, sluznico ali očmi, je treba kožo takoj umiti z milom in vodo, sluznico ali oči pa izprati z vodo.
Reinstitution of ETOPOPHOS and associated names therapy should be carried out with caution, and with adequate consideration of the further need for the drug and close attention to possible recurrence of toxicity.
Ponovno zdravljenje z zdravilom ETOPOPHOS in povezana imena uvedemo previdno in po presoji bolnikove potrebe po nadaljnjem zdravljenju, pri tem pa skrbno pazimo, da se neželeni učinki ne bi ponovili.
Etoposide has been shown to cause metaphase arrest in chick fibroblasts.
Dokazali so, da etopozid na piščančjih fibroblastih povzroča zaustavljanje delitve v metafazi.
There is the potential for serious adverse reactions in nursing infants from ETOPOPHOS and associated names.
Obstaja možnost resnih neželenih učinkov, ki jih zdravilo ETOPOPHOS in povezana imena lahko povzroči pri dojenem otroku.
• breathing problems
• težave s požiranjem
Patients being treated with ETOPOPHOS and associated names must be observed for myelosuppression carefully and frequently both during and after therapy.
Bolnike je treba skrbno in pogosto spremljati glede znakov mielosupresije med in po zdravljenju z zdravilom ETOPOPHOS in povezana imena.
ETOPOPHOS and associated names should be terminated immediately, followed by the administration of pressor agents, corticosteroids, antihistamines, or volume expanders at the discretion of the physician.
Zdravljenje z zdravilom ETOPOPHOS in povezana imena je treba takoj ukiniti, po presoji zdravnika pa uporabiti zdravila za zvišanje krvnega tlaka, kortikosteroide, antihistaminike in plazemske ekspanderje.
• bleeding Rare side effects (affecting between 1 in 1,000 and 1 in 10,000 people)
Redki neželeni učinki (pojavijo se pri manj kot 1 od 1000 bolnikov in več kot 1 od 10.000 bolnikov)
Possible side effects experienced with ETOPOPHOS and associated names that are;
Možni neželeni učinki, ki so jih opazili pri zdravljenju z zdravilom ETOPOPHOS in povezana imena, ki so
• diarrhoea
• okužba
ETOPOPHOS and associated names should not be administered to patients with neutrophil counts less than 1,500 cells/mm3
Zdravila ETOPOPHOS in povezana imena se ne sme dajati bolnikom s številom nevtrofilcev pod 1.500 celic/mm3 ali s številom trombocitov pod 100.000 celic/mm3, razen v primeru, ko je število celic zmanjšano zaradi maligne bolezni.
• 0.9% sodium chloride solution.
• natrijevega klorida 9 mg/ml (0,9 %) raztopina.
Administration Precautions: As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of ETOPOPHOS and associated names.
Previdnostni ukrepi pri dajanju: Pri ravnanju in pripravi raztopine zdravila ETOPOPHOS in povezana imena je potrebna previdnost, tako kot velja za vse potencialno toksične spojine.
After intravenous administration of 14C etoposide (100 to 124 mg/m2), mean recovery of radioactivity in the urine was
Po intravenski aplikaciji 14Cetopozida (100 do 124 mg/m2) je bila srednja vrednost reaktivnega odmerka v urinu 56 % v 120 urah, v blatu pa 44 % v 120 urah.
The following adverse reactions were reported from ETOPOPHOS and associated names clinical studies and post-marketing experience.
V kliničnih študijah z zdravilom ETOPOPHOS in povezana imena in v obdobju trženja zdravila so poročali o naslednjih neželenih učinkih.
Fertility
etopozid
Anaphylactic reactions (see section 4.4), manifested by chills, tachycardia, bronchospasm, dyspnoea, diaphoresis, pyrexia, pruritus, hypertension or hypotension, syncope, nausea, and vomiting have been reported to occur in 3% (7 of 245 patients treated with ETOPOPHOS and associated names in 7 clinical studies) of patients treated with ETOPOPHOS and associated names.
so poročali pri 3 % (7 od 245 bolnikov, zdravljenih z zdravilom ETOPOPHOS in povezana imena v 7 kliničnih študijah) bolnikov, zdravljenih z zdravilom ETOPOPHOS in povezana imena.
ETOPOPHOS and associated names (see Annex I) 100 mg powder for solution for infusion ETOPOPHOS and associated names (see Annex I) 1000 mg powder for solution for infusion
ETOPOPHOS in povezana imena (glejte Prilogo I) 100 mg prašek za raztopino za infundiranje ETOPOPHOS in povezana imena (glejte Prilogo I) 1000 mg prašek za raztopino za infundiranje
The resulting stock solution may be administered without further dilution or can be further diluted with 5% glucose solution or 0.9% sodium chloride solution to a final concentration 0.1 mg/ml etoposide.
Raztopino lahko tudi nadalje razredčite z glukozo 50 mg/ml (5 %) raztopina ali natrijevim kloridom 9 mg/ml (0,9 %) do končne koncentracije 0,1 mg/ml etopozida.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of first line, recurrent or refractory testicular cancer in adults.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za prvo linijo zdravljenja rekurentnega ali refraktarnega raka mod pri odraslih.
What ETOPOPHOS and associated names looks like and contents of the pack
Izgled zdravila ETOPOPHOS in povezana imena in vsebina pakiranja
Acute fatal reactions associated with bronchospasm have also been reported with etoposide phosphate.
Pri zdravljenju z etopozid fosfatom so poročali tudi o akutnih reakcijah z bronhospazmom, ki so se končale s smrtjo.
Each vial contains 1136 mg etoposide phosphate equivalent to 1000 mg etoposide.
Ena viala vsebuje 1000 mg etopozida v obliki 1136 mg etopozid fosfata.
Anaphylactic reactions have been reported to occur during or immediately after intravenous administration of etoposide phosphate.
Med intravenskim dajanjem etopozid fosfata ali takoj po njem so bile opisane reakcije anafilaktičnega tipa.
6.6 Special precautions for disposal and other handling Procedures for proper handling and disposal of anti-cancer drugs should be followed.
6.6 Posebni varnostni ukrepi za odstranjevanje <in ravnanje z zdravilom
• 5% glucose solution or
• glukoze 50 mg/ml (5 %) raztopina ali
infections, or at a thrombocyte count below 25,000 cells/mm3, which is not caused by the disease.
Poleg tega je treba odmerek prilagoditi, če se pojavijo zvišana telesna temperatura, okužbe ali če je število trombocitov nižje od 25.000 celic/mm3 razen v primeru, ko je število celic zmanjšano zaradi same bolezni.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje drobnoceličnega pljučnega raka pri odraslih.
See Annex I - To be completed nationally
Glejte Prilogo I - izpolni država članica.
The recommended dose of ETOPOPHOS and associated names in adult patients is 50 to 100 mg/m2/day (etoposide equivalent) on days 1 to 5 or 100 to 120 mg/m2 on days 1, 3, and 5 every 3 to 4
Priporočeni odmerek zdravila ETOPOPHOS in povezana imena pri odraslih bolnikih je 50 do 100 mg/m2/dan (ekvivalent etopozida), 1. do 5. dan ali 100 do 120 mg/m2, 1., 3. in 5. dan na vsake 3 do 4 tedne v kombinaciji z drugimi zdravili, odobreni za uporabo pri zdravljeni bolezni.
You must not breastfeed while you are receiving ETOPOPHOS and associated names.
Med jemanjem zdravila ETOPOPHOS in povezana imena ne smete dojiti.
ETOPOPHOS and associated names is used in the treatment of certain types of cancers in adults:
Zdravilo ETOPOPHOS in povezana imena uporabljamo za zdravljenje določenih vrst raka pri odraslih: - rak mod
After reconstitution, the solution can be administered without further dilution or it can be further diluted with 5% glucose solution or 0.9% sodium chloride solution to obtain concentrations as low as 0.1 mg/ml etoposide.
Raztopino lahko tudi nadalje razredčite z glukozo 50 mg/ml (5 %) raztopina ali natrijevim kloridom 9 mg/ml (0,9 %), da boste dobili nizke koncentracije 0,1 mg/ml etopozida.
Uncommon side effects (affecting between 1 in 100 and 1 in 1000 people) • tingling or numbness in hands and feet
Pogosti neželeni učinki (pojavijo se pri manj kot 1 od 10 bolnikov in več kot 1 od 100 bolnikov) • akutna levkemija
ETOPOPHOS and associated names 100mg Powder for Solution for Infusion ETOPOPHOS and associated names 1000mg Powder for Solution for Infusion [See Annex I - To be completed nationally]
ETOPOPHOS in povezana imena 100 mg prašek za raztopino za infundiranje ETOPOPHOS in povezana imena 1000 mg prašek za raztopino za infundiranje [Glejte Prilogo I - izpolni država članica.]
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION ETOPOPHOS and associated names 100 mg powder for solution for infusion [See Annex I - To be completed nationally]
IME ZDRAVILA IN POT(I) UPORABE ETOPOPHOS in povezana imena 100 mg prašek za raztopino za infundiranje [Glejte Prilogo I - izpolni država članica.]
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of acute myeloid leukaemia in adult and paediatric patients.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje akutne mieloblastne levkemije pri odraslih in pri pediatričnih bolnikih.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION ETOPOPHOS and associated names 1000 mg powder for solution for infusion [See Annex I - To be completed nationally]
IME ZDRAVILA IN POT(I) UPORABE ETOPOPHOS in povezana imena 1000 mg prašek za raztopino za infundiranje [Glejte Prilogo I - izpolni država članica.]
Sodium citrate
SEZNAM POMOŽNIH SNOVI natrijev citrat dekstran 40
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of non-Hodgkin's lymphoma in adult and paediatric patients.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje ne-Hodgkinovega limfoma pri odraslih in pri pediatričnih bolnikih.
Administration and Dosage
Dajanje in odmerjanje
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label (1000 mg)
Nalepka na viali (1000 mg)
ETOPOPHOS and associated names is indicated for first line and second line therapy in combination with other approved chemotherapeutic agents for the treatment of high risk gestational trophoblastic neoplasia in adults.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za prvo in drugo linijo zdravljenja visokotvegane gestacijske trofoblastne neoplazije.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of Hodgkin's lymphoma in adult and paediatric patients.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje Hodgkinovega limfoma pri odraslih in pri pediatričnih bolnikih.
What ETOPOPHOS and associated names is and what it is used for
Kaj je zdravilo ETOPOPHOS in povezana imena in za kaj ga uporabljamo To zdravilo se imenuje ETOPOPHOS in povezana imena.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults.
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje neepitelijskega raka jajčnikov pri odraslih.
Nadirs tend to occur earlier with intravenous administration compared to oral administration.
Najnižje vrednosti se običajno pojavijo prej v primeru intravenske kot v primeru peroralne uporabe.
The usual dose, based on etoposide, is 50 to100mg/m2 body surface area, daily for 5 days in a row or 100 to 120 mg/ m2 body surface area on days 1, 3 and 5.
Običajni odmerek, ki temelji na etopozidu, je 50 do 100 mg/m2 telesne površine dnevno, 5 dni zapored ali 100 do 120 mg/m2 telesne površine 1., 3. in 5. dan. Cikel zdravljenja se nato lahko ponovi glede na rezultate krvnih preiskav, vendar ne prej kot 21 dni po zaključku prvega cikla zdravljenja.
Date
DRUGI PODATKI
Reports of fever and infection were also very common in patients with neutropenia treated with etoposide phosphate.
Pri bolnikih z nevtropenijo, ki so se zdravili z etopozid fosfatom, so zelo pogosto poročali o zvišani telesni temperaturi in okužbah.
ETOPOPHOS and associated names contains
ETOPOPHOS in povezana imena.
• constipation
• krvavitev
- if you are taking any drugs with a similar mechanism of action as ETOPOPHOS and associated names.
- Če jemljete katera koli zdravila s podobnim načinom delovanja, kot ga ima zdravilo
STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains etoposide 100 mg (as phosphate) Each vial contains etoposide 1000 mg (as phosphate)
NAVEDBA ENE ALI VEČ UČINKOVIN Ena viala vsebuje 100 mg etopozida (v obliki fosfata).
Each vial contains etoposide phosphate equivalent to etoposide 100 mg or 1000 mg as the active ingredient.
Ena viala vsebuje 100 mg ali 1000 mg etopozida v obliki etopozid fosfata.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label (100 mg)
Nalepka na viali (100 mg)
How to store ETOPOPHOS and associated names
Kaj vsebuje zdravilo ETOPOPHOS in povezana imena
Fatal myelosuppression has been reported following etoposide phosphate administration.
Po dajanju etopozid fosfata so poročali o smrti zaradi mielosupresije.
Myelosuppression (see section 4.4) with fatal outcome has been reported following administration of etoposide phosphate.
Po uporabi etopozid fosfata so poročali o smrti zaradi mielosupresije (glejte poglavje 4.4).
December 2025
decembra 2025
June 2020
junija 2020
Aseptic technique must be used.
Uporabiti je treba aseptično tehniko.
Adults >21 years
Odrasli, stari > 21 let
t1/2 (day)
t1/2 (dni)
Ask your doctor for advice on the best contraceptive method that you can use.
Posvetujte se z zdravnikom o najboljši kontracepcijski metodi, ki jo lahko uporabite.
There are no data available for elderly patients.
Podatki za starejše bolnike niso na voljo.
8 months.
8 mesecev
It should only be given in a hospital setting where appropriate resuscitation equipment is available.
Zdravilo se lahko daje samo v bolnišnici, kjer je na voljo primerna oprema za oživljanje.
Your physician will decide whether your disease requires treatment.
Zdravnik bo presodil, ali je treba vašo bolezen zdraviti.
Therapeutic efficacy was defined as a clinical improvement which did not meet the criteria for other beneficial outcomes.
Terapevtska učinkovitost je bila opredeljena kot klinično izboljšanje, ki ne izpolnjuje meril za druge ugodne izide.
In very rare cases, mild tremor in the fingers has been described.
V zelo redkih primerih je bil opisan blag tremor v prstih.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 January 2016
Datum prve odobritve: 14. januar 2016
Alteration of liver parameters is common.
Spremembe jetrnih parametrov so pogoste.
Medical equipment to treat allergic reactions will be available nearby.
V bližini bo na voljo medicinska oprema za zdravljenje alergijskih reakcij.
Patients should be monitored for changes in liver function parameters.
Bolnike moramo spremljati za spremembe v parametrih jetrne funkcije.
Not known: Pyrexia
Neznana: pireksija
Staff should be trained in how to handle and transfer the medicinal product (pregnant staff should be excluded from working with this medicinal product).
Osebje je treba usposobiti za ravnanje z zdravilom in njegov prenos (nosečnice s tem zdravilom ne smejo delati).
If higher volume is given, the dose should be divided and given at several injection sites.
Če dajemo večji volumen, moramo odmerek razdeliti in ga dati na več mestih injiciranja.
All items for administration or cleaning, including gloves, should be placed in high-risk waste disposal bags for high-temperature incineration.
Vse predmete, namenjene dajanju ali čiščenju, vključno z rokavicami, je treba odložiti v vreče za odpadke z visokim tveganjem, namenjene sežiganju pri visokih temperaturah.
In general, incidence and type of adverse reactions Grade 3 and 4 were similar between the two treatment groups.
Na splošno sta bili pojavnost in vrsta neželenih učinkov 3. in 4. stopnje podobni v obeh skupinah zdravljenja.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden uporabite to zdravilo.
The proportion of patients with this level of depletion was similar between the 2 study arms during all 3 phases of treatment at the protocol-specified time points.
Delež bolnikov s takšnim upadom je bil podoben v obeh skupinah študije v vseh 3 fazah zdravljenja ob časovnih točkah, opredeljenih v protokolu.
Tell your doctor if any of these conditions apply to you.
Obvestite zdravnika, če kaj od navedenega velja za vas.
ALL is a white blood cell cancer type in which certain immature white cells (named lymphoblasts) start growing out of control thus preventing the production of functional blood cells.
ALL je vrsta raka belih krvnih celic, pri katerem se začne število določenih nezrelih belih krvnih celic (imenovanih limfoblasti) nenadzorovano povečevati in s tem prepreči nastajanje delujočih krvnih celic.
This can promote the tendency to bleeding and/or thrombosis.
To lahko spodbuja nagnjenost h krvavitvam in/ali k trombozi.
During Oncaspar administration you will be closely watched for an hour after the start of treatment for any signs of serious allergic reactions.
Med dajanjem zdravila Oncaspar vas bodo eno uro po začetku zdravljenja natančno spremljali glede morebitnih znakov resne alergijske reakcije.
This leaflet was last revised in
Navodilo je bilo nazadnje revidirane dne
You should not use Oncaspar if you are pregnant because its effects during pregnancy have not been studied.
Zdravila Oncaspar ne smete uporabljati, če ste noseči, ker njegovih učinkov med nosečnostjo niso preučevali.
Normal cells can make asparagine for themselves, while some cancer cells cannot.
Normalne celice lahko same proizvajajo asparagin, nekatere rakave celice pa ga ne morejo.
Men must also use effective contraception while they or their partners are treated with Oncaspar.
Tudi moški morajo uporabljati učinkovito kontracepcijo, medtem ko se sami ali njihove partnerice zdravijo z zdravilom Oncaspar.
If symptoms of hyperammonaemia exist, ammonia levels should be monitored closely.
Če se pojavijo simptomi hiperamoniemije, moramo ravni amoniaka natančno spremljati.
- vincristine, another cancer medicine.
- vinkristin (drugo zdravilo za raka).
In case of overdose, patients must be carefully monitored for signs and symptoms of adverse reactions, and appropriately managed with symptomatic and supportive treatment.
V primeru prevelikega odmerjanja moramo bolnike skrbno spremljati glede znakov in simptomov neželenih učinkov in jih ustrezno obravnavati s simptomatskim in podpornim zdravljenjem.
Cmax (mU/mL)* Tmax (hr)*
Cmax (me./ml)* Tmax (h)*
Warning: special handling instructions (see package leaflet)
Opozorilo: posebna navodila za ravnanje (glejte navodilo za uporabo).
Elderly There are limited data available for patients older than 65 years.
Starejši bolniki Podatkov pri bolnikih, starejših od 65 let, je malo.
In severe cases, encephalopathy can develop with or without hepatic impairment, especially in older adults, which can be life-threatening or fatal.
V hudih primerih se lahko pojavi encefalopatija z jetrno okvaro ali brez nje, zlasti pri starejših bolnikih, ki je lahko življenjsko nevarna ali smrtna.
The controlled studies were not designed to formally evaluate the pharmacokinetics of Oncaspar in specific populations.
Nadzorovane študije niso bile načrtovane za formalno ocenjevanje farmakokinetike zdravila Oncaspar v specifičnih populacijah.
Investigations of the effect on fertility and peri- and postnatal development were not conducted.
Raziskave učinkov na plodnost in peri-/postnatalni razvoj niso bile opravljene.
Therefore, vincristine should be given at least 12 hours prior to administration of Oncaspar in order to minimise toxicity.
Zato je treba vinkristin dati vsaj 12 ur pred dajanjem zdravila Oncaspar, da se toksičnost zmanjša na najmanjšo možno mero.
Due to the risk of hyperbilirubinaemia, it is recommended to monitor bilirubin levels at baseline and prior to each dose.
Zaradi tveganja za hiperbilirubinemijo je priporočljivo spremljati ravni bilirubina na začetku in pred vsakim odmerkom.
If these substances are given subsequently, the effect of pegaspargase can be weakened antagonistically.
Če ti učinkovini damo naknadno, je lahko učinek pegaspargaze antagonistično oslabljen.
In the unlikely event of accidental overdose, you will be monitored carefully by medical staff and treated appropriately.
V malo verjetnem primeru nenamernega prevelikega odmerjanja vas bo zdravstveno osebje skrbno spremljalo in ustrezno zdravilo.
Severe hepatic impairment (bilirubin >3 times upper limit of normal [ULN]; transaminases >10 times ULN).
Huda jetrna okvara (bilirubin > 3-kratna zgornja meja normalnih vrednosti [ULN]; transaminaze > 10-kratna ULN).
Reduced splenic weight might be a sign of potential immunosuppressant effect of the treatment.
Zmanjšana masa vranice je lahko znak potencialnega imunosupresivnega učinka zdravljenja.
Oncaspar is used together with other medicines.
Zdravilo Oncaspar se uporablja skupaj z drugimi zdravili.